Inhibiting progression of coronary calcification using Aged Garlic Extract in patients receiving statin therapy: a preliminary study
Inhibiting progression of coronary calcification using Aged Garlic Extract in patients receiving statin therapy: a preliminary study
复制标题
DOI：
10.1016/j.ypmed.2004.04.012
复制
发表时间：
2004-11-01
影响因子：
5.1
通讯作者：
Amagase, H
中科院分区：
文献类型：
--
作者：
Budoff, MJ;Takasu, J;Amagase, H
背景老化大蒜提取物（AGE）可降低多种心血管风险因素，包括血压，胆固醇，血小板聚集和粘附，同时刺激内皮细胞中一氧化氮的产生。然而，没有研究评估AGE抑制血管钙化的能力，血管钙化是人类冠状动脉斑块形成的标志物。评估老化大蒜提取物（AGE）与安慰剂相比改变动脉粥样硬化进展速率的功效。一项安慰剂对照、双盲、随机化初步研究，旨在确定与安慰剂相比，在AGE的影响下，通过电子束断层扫描（EBT）检测到的动脉粥样硬化斑块负荷是否会以不同的速率变化。23例患者入组，19例患者完成了研究方案。给予受试者AGE 4 ml或等量安慰剂。研究持续时间为1年。S-烯丙基半胱氨酸（SAC）是AGE的活性化合物之一，作为依从性标志物在血液中进行测量。结果。AGE组（n = 9）1年内钙评分（容量法）的平均变化为7.5 ± 9.4%。安慰剂组（n = 10）表现出钙评分平均增加22.2 +/-18.5%，显著高于治疗组（P = 0.046）。两组之间的个体胆固醇参数或C反应蛋白无显著差异。在随机分配至AGE组的患者中，胆固醇/高密度脂蛋白比值（P = 0.07）和同型半胱氨酸水平（P = 0.08）的改善趋势不显著。这项小型初步研究表明，与安慰剂相比，AGE在1年内抑制冠状动脉钙化进展速度的潜在能力。如果这些发现在更大规模的研究中得到扩展和证实，大蒜可能对未来心血管事件风险高的患者有用。(C)2004年癌症预防研究所和爱思唯尔公司。All rights reserved.
Background. Aged Garlic Extract (AGE) reduces multiple cardiovascular risk factors, including blood pressure, cholesterol, platelet aggregation and adhesion, while stimulating nitric oxide generation in endothelial cells. However, no study has evaluated the ability of AGE to inhibit vascular calcification, a marker of plaque formation in human coronary arteries.Objective. To assess the efficacy of Aged Garlic Extract (AGE) on changing the rate of atherosclerosis progression as compared to placebo.Design. A placebo-controlled, double-blind, randomized pilot study to determine whether the atherosclerotic plaque burden detected by electron beam tomography (EBT) will change at a different rate under the influence of AGE as compared to placebo. Twenty-three patients were enrolled, and 19 patients completed the study protocol. AGE 4 ml or the equivalent amount of placebo was given to subjects. Duration of the study was 1 year. S-allylcysteine (SAC), one of the active compound of AGE, was measured in the blood as a compliance marker.Results. The mean change of the calcium score (volumetric method) for the AGE group (n = 9) was 7.5 +/- 9.4% over 1 year. The placebo group (n = 10) demonstrated an average increase in calcium scores of 22.2 +/- 18.5%, significantly greater than the treated cohort (P = 0.046). There were no significant differences in individual cholesterol parameters or C reactive protein between the groups. In patients randomized to AGE, there was a nonsignificant trend for improving cholesterol/high-density lipoprotein ratio (P = 0.07) and homocysteine level (P = 0.08).Conclusions. This small pilot study indicates the potential ability of AGE to inhibit the rate of progression of coronary calcification, as compared to placebo over 1 year. Should these findings be extended and confirmed in larger studies, garlic may prove useful for patients who are at high risk of future cardiovascular events. (C) 2004 The Institute For Cancer Prevention and Elsevier Inc. All rights reserved.